Kilobaser vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
Kilobaser logo

Kilobaser

EmergingHealthcare

General

Vienna Austria YC W21 desktop DNA synthesizer enabling on-demand oligo production in research labs at $3.1M revenue 2024; $1.99M BioTools Innovator-backed "Nespresso for DNA" at $35.5-49.5K competing with IDT and Evonetix for benchtop DNA synthesis.

AI VisibilityBeta
Overall Score
D39
Category Rank
#410 of 596
AI Consensus
82%
Trend
up
Per Platform
ChatGPT
33
Perplexity
38
Gemini
41

About

Kilobaser is a Vienna, Austria-based biotechnology hardware company — backed by Y Combinator (W21) with $1.99 million in total funding from BioTools Innovator — providing research laboratories and life sciences companies with desktop DNA and RNA oligonucleotide synthesizers that enable individual scientists to produce custom synthetic DNA sequences directly on their benchtops without sending samples to commercial synthesis services, generating $3.1 million in annual revenue in 2024 with consistent revenue growth since the 2014 company founding. Positioned as the "Nespresso Machine for DNA," Kilobaser offers the Basic Edition synthesizer ($35,500) and Extended Edition ($49,500) — compact, affordable instruments that democratize access to on-demand DNA synthesis for research labs that need rapid turnaround on custom oligonucleotide sequences for PCR primers, CRISPR guides, sequencing adapters, and synthetic gene construction.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#410
Category Rank
#2
82
AI Consensus
83
up
Trend
up
33
ChatGPT
92
38
Perplexity
93
41
Gemini
89
39
Claude
96
38
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.